MRK Merck and Co Inc

By Mauro Orru

Bayer AG said Thursday that the U.S. Food and Drug Administration granted priority review to the new drug application for vericiguat to treat chronic heart failure.

The German pharmaceutical and chemical company said vericiguat is being developed with Merck Sharp Dohme Pharma, a subsidiary of Merck & Co. Inc.

The FDA decision means the body aims to take action on an application within six months of acceptance instead of 10 months under a standard review, Bayer said, setting a target action date for Jan. 20, 2021.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

July 16, 2020 07:27 ET (11:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.